Revvity, Inc. (RVTY)
| Market Cap | 17.03B +59.3% |
| Revenue (ttm) | 2.91B +4.1% |
| Net Income | 237.55M -16.7% |
| EPS | 2.09 -11.5% |
| Shares Out | 111.59M |
| PE Ratio | 72.93 |
| Forward PE | 27.07 |
| Dividend | $0.28 (0.18%) |
| Ex-Dividend Date | Oct 23, 2026 |
| Volume | 1,336,608 |
| Open | 154.44 |
| Previous Close | 154.71 |
| Day's Range | 151.61 - 155.50 |
| 52-Week Range | 81.22 - 166.25 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 147.53 (-3.35%) |
| Earnings Date | Nov 3, 2026 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, i... [Read more]
Financial Performance
In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $147.53, which is a decrease of -3.35% from the latest price.
News
How to Invest in AI Drug Discovery
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operat...
Revvity price target raised to $175 from $130 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Revvity (RVTY) to $175 from $130 and keeps a Buy rating on the shares. The firm adjusted targets in…
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 20...
Revvity price target raised to $165 from $125 at BofA
BofA raised the firm’s price target on Revvity (RVTY) to $165 from $125 and keeps a Neutral rating on the shares. The life science tools sector has further re-rated since…
Revvity price target raised to $160 from $115 at Barclays
Barclays raised the firm’s price target on Revvity (RVTY) to $160 from $115 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the life science…
Revvity to Host Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity's senior ma...
Revvity initiated with an Outperform at William Blair
William Blair initiated coverage of Revvity (RVTY) with an Outperform rating. The firm sees the company’s 2026 organic growth estimates proving conservative. As Revvity’s two life sciences end markets...
Revvity to Hold Earnings Call on November 3, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Compan...
Revvity launches GSP T1D 3plex kit
Revvity (RVTY) announced the launch of the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody detection solution to enable population-wide screening programs that identify...
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution ...
Revvity Transcript: 2026 Global Healthcare Conference
The company reported strong Q2 results, driven by diagnostics and a recovering life sciences segment, with significant backlog in high-content screening instruments and robust growth in China. Software innovation and AI integration are accelerating, while operational improvements and strategic acquisitions position the business for future organic growth.
Revvity Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed into an innovation-focused life sciences and diagnostics leader, with strong growth in reagents, software, and diagnostics, and a strategic emphasis on AI integration. Margin expansion, portfolio optimization, and a robust software business are key drivers for future performance.
Revvity Transcript: Wells Fargo 21st Annual Healthcare Conference
A tuck-in acquisition strengthens the reagents portfolio, while AI-driven demand is accelerating growth in high-content screening and software. Diagnostics and reproductive health segments remain robust, and margin guidance has been raised on strong execution. SaaS transition and new AI-based products are set to drive future growth.
Revvity assumed with a Neutral at UBS
UBS assumed coverage of Revvity (RVTY) with a Neutral rating and $140 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views life science…
Revvity to acquire Human Cell Design
Revvity (RVTY) announced it has entered into a definitive agreement to acquire Human Cell Design, or HCD, a France-based biotechnology company specializing in human cell models and preclinical researc...
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company sp...
Revvity price target raised to $165 from $125 at KeyBanc
KeyBanc raised the firm’s price target on Revvity (RVTY) to $165 from $125 and keeps an Overweight rating on the shares. The firm hosted an NDR with Revvity this week,…
Revvity initiated with a Sector Perform at RBC Capital
RBC Capital analyst Dan Leonard initiated coverage of Revvity (RVTY) with a Sector Perform rating and $135 price target The neutral rating reflects the durability of Revvity’s “high-quality” franchise...
Revvity management to meet with KeyBanc
Meeting to be held in Detroit on September 1 and in Milwaukee on September 2 hosted by KeyBanc.
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-qualit...
Revvity price target raised to $126 from $125 at Evercore ISI
Evercore ISI raised the firm’s price target on Revvity (RVTY) to $126 from $125 and keeps an Outperform rating on the shares.
Revvity price target raised to $110 from $100 at Stifel
Stifel raised the firm’s price target on Revvity (RVTY) to $110 from $100 and keeps a Hold rating on the shares.
Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Medical equipment maker Revvity raised its annual profit and revenue forecasts on Tuesday, after topping Wall Street estimates for the second quarter helped by improving demand for its drug-developm...
Revvity Earnings Call Transcript: Q2 2026
Q2 2026 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong Diagnostics and AI-related demand in Life Sciences. Full-year outlook was raised for organic growth, margins, and EPS, with robust cash flow and a pending China Immunodiagnostics divestiture.
Revvity Slides: Q2 2026
Revvity has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.